Protalix BioTherapeutics (PLX), Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label Trial Evaluating Pegunigalsidase

Go back to Protalix BioTherapeutics (PLX), Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label Trial Evaluating Pegunigalsidase
POWERSHARES GLOBAL CLEAN ENERGY PORTFOLIO (NYSE: PBD) Delayed: 28.75 -0.06 (0.21%)
Previous Close $28.81    52 Week High $11.63 
Open $28.98    52 Week Low $9.19 
Day High $29.12    P/E N/A 
Day Low $28.69    EPS $0.00 
Volume 66,579       

PROTALIX BIOTHERAPEUTICS, INC. COMMON STOCK (NYSE: PLX) Delayed: 3.02 +0.07 (2.37%)
Previous Close $2.95    52 Week High $1.11 
Open $2.98    52 Week Low $0.41 
Day High $3.13    P/E N/A 
Day Low $2.95    EPS $-0.29 
Volume 1,237,763